The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas

@article{Sarno2000TheEO,
  title={The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas},
  author={A. di Sarno and M. L. Landi and P. Marzullo and C. Di Somma and R. Pivonello and G. Cerbone and G. Lombardi and A. Colao},
  journal={Clinical Endocrinology},
  year={2000},
  volume={53}
}
To compare effectiveness and tolerability of quinagolide (CV 205–502) and cabergoline (CAB) treatments in 39 patients with prolactinoma. 
View on Wiley
ncbi.nlm.nih.gov
77 Citations
Highly Influential Citations
3
Background Citations
15
Methods Citations
3
Results Citations
2

77 Citations

Citation Type

Citation Type

Factors determining the remission of microprolactinomas after dopamine agonist withdrawal
  • 28
When can we stop cabergoline treatment in prolactinomas?
  • 6
Cabergoline
Management of resistant prolactinomas
  • 37
Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy
  • 71
Dopamine receptor agonists for treating prolactinomas
  • 112
Clinical Pharmacokinetics of Cabergoline
  • 48
Giant prolactinomas in men: efficacy of cabergoline treatment
  • 118
Management of Dopamine Agonist-Resistant Prolactinoma
  • 27
Hyperprolactinemia and prolactinomas.
  • 147
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study
  • 49
Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine
  • 31
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
  • 225
  • PDF
Growth-hormone and prolactin excess
  • 231
  • PDF
Drugs five years later. Bromocriptine.
  • 208
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
  • 43
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
  • 40
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
  • 27
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
  • 119
Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
  • 24
...
1
2
3
4
...